Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)

A Form XXII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuKa radiation:

• 10.0, 16.1, and 19.2, and a solid state 19F nuclear magnetic resonance having the following chemical shifts expressed in parts per million:
• −112.0, −114.8, and −118.9.

A Form XXII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuKa radiation:

• 4.0, 4.9, 8.0, 10.0, 11.1, 11.7, 12.2, 13.1, 13.5, 14.0, 14.8, 16.1, 16.4, 17.0, 17.4, 17.7, 19.2, 20.0, 20.3, 21.3, 22.6, 24.5, 27.0, 28.1, 28.9, and 29.4.

A Form XXII atorvastatin calcium having a solid state 13C nuclear magnetic resonance having the following chemical shifts expressed in parts per million:

• 182.1, 166.6, 164.1, 161.8, 143.7, 139.4, 136.1, 134.2, 129.1, 123.4, 119.7, 115.7, 68.7, 45.1, 43.9, 39.1, 37.4, 26.8, 22.7, 20.6, and 18.3.

A Form XXII atorvastatin calcium characterized by Raman spectroscopy having the following peaks expressed in cm−1:

• 618, 820, 855, 998, 1033, 1157, 1243, 1364, 1410, 1526, 1603, 1671, and 3059.

A Form XXII atorvastatin calcium a solid state 19F nuclear magnetic resonance having the following chemical shifts expressed in parts per million:

• −112, −114.8, −118.9.